Scynexis Inc

NASDAQ:SCYX USA Drug Manufacturers - Specialty & Generic
Market Cap
$38.63 Million
Market Cap Rank
#23246 Global
#8148 in USA
Share Price
$0.92
Change (1 day)
+2.39%
52-Week Range
$0.58 - $1.18
All Time High
$70.50
About

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory inva… Read more

Scynexis Inc (SCYX) - Cash Flow Conversion Efficiency

Latest cash flow conversion efficiency as of December 2025: 0.373x

Based on the latest financial reports, Scynexis Inc (SCYX) has a cash flow conversion efficiency ratio of 0.373x as of December 2025.

Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($18.40 Million) by net assets ($49.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Scynexis Inc - Cash Flow Conversion Efficiency Trend (2012–2025)

This chart illustrates how Scynexis Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

Scynexis Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Scynexis Inc ranked by their cash flow conversion efficiency.

Annual Cash Flow Conversion Efficiency for Scynexis Inc (2012–2025)

The table below shows the annual cash flow conversion efficiency of Scynexis Inc from 2012 to 2025.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $49.38 Million $-5.28 Million -0.107x +75.46%
2024-12-31 $55.08 Million $-24.01 Million -0.436x -152.87%
2023-12-31 $72.96 Million $60.16 Million 0.825x +103.34%
2022-12-31 $3.23 Million $-79.88 Million -24.709x -1768.45%
2021-12-31 $41.26 Million $-54.56 Million -1.322x +39.02%
2020-12-31 $22.76 Million $-49.35 Million -2.169x +26.64%
2019-12-31 $12.89 Million $-38.12 Million -2.956x -225.90%
2018-12-31 $31.23 Million $-28.32 Million -0.907x +20.91%
2017-12-31 $21.41 Million $-24.56 Million -1.147x -36.05%
2016-12-31 $34.82 Million $-29.35 Million -0.843x -44.08%
2015-12-31 $41.95 Million $-24.55 Million -0.585x -106.51%
2014-12-31 $33.43 Million $-9.47 Million -0.283x -157.23%
2013-12-31 $-8.70 Million $-4.31 Million 0.495x -9.69%
2012-12-31 $-19.33 Million $-10.60 Million 0.548x --